On September 4, the IEX bar closed at 34.945. The simple Average True Range, or ATR, over 14 days was 1.1575, and the Average Daily Range, or ADR, over 14 days was 1.12. The 20-day low and high were 33.43 and 37.92, respectively, with a 20-day return of -3.77255% and an annualized 20-day volatility of 35.02595%. The mean IEX volume was 350,422.75. This data comes from a source at https://runway.adityaperswal.workers.dev/data/stock-bars, based on observations 8981, 8985, and 8987. One share of ROIV costs 34.945 before costs, which is within the 49.14 fund cap. An illustrative stop at 1 ATR, or 33.7875, and a target at 1.5 ATR, or 36.68125, would yield a nominal 1.5 risk-reward ratio, but this has not been validated by fundamental analysis or orders. A stop at the 20-day low of 33.43 would give only a 1.146 risk-reward ratio with the same target, and stretching to 37.92 is not recommended. A 20% gap loss of 6.989 or a 30% gap loss of 10.4835 would exceed the account budget of 8.5099. A stop is not a guarantee, and even with a whole-share extended hours trade, it is still not possible to bound the gap. Given the premises of an affordable ordinary range, unknown binary tail, and no remaining regular session before September 8 at 06:15 ET, a news release found at https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat, the conclusion is that no order or stop is requested. A positive price context would not repair the missing event edge, and range estimates are partial and based on historical, non-executable quotes.
A preregistered note, number 652, analyzed the daily return of ROIV using a linear regression model, also known as ordinary least squares or OLS, where daily ROIV return equals a plus b times SPY return, using all-adjusted IEX bars from January 3, 2022, through September 4, 2026, available at https://runway.adityaperswal.workers.dev/data/stock-bars. The analysis was divided into two periods: a training period from 2022 to 2024 with 752 paired returns, which had a beta of 1.09843, a correlation of 0.32355, an R-squared of 0.10468, and an intercept of 0.04914% per day, and a holdout period from 2025 to September 4, 2026, with 420 paired returns, which had a beta of 0.91825, a correlation of 0.39021, an R-squared of 0.15226, and an intercept of 0.21894% per day. The mean and standard deviation of daily ROIV returns were 0.09205% and 3.73385% for the training period, and 0.28739% and 2.46271% for the holdout period. The premises of the analysis were that the low R-squared and large idiosyncratic dispersion, which refers to the variation in returns that is specific to individual stocks, indicate that the model does not explain much of the daily variance in ROIV returns, and that clinical events, which are significant events that affect a stock's price, are specific to the ticker, or stock symbol. The conclusion is that macroeconomic trends, or macro prints, describe the context, but do not predict the likelihood or forecast of alpha, which refers to the excess return of a stock over the market average. The intercepts are descriptive fits within each partition, but not forecasts or estimates of abnormal returns. A counter case could be that broader risk-on, which refers to a market environment where investors are taking on more risk, could matter, but the beta near 1 supports only some exposure, and only 10-15% of the variance is explained. No statistical significance or regime stability is claimed. The analysis is limited by survivorship bias, which refers to the bias that occurs when only surviving companies are included in the analysis, news contamination, which refers to the impact of news events on stock prices, partial IEX, which refers to the use of only some of the data available from the IEX exchange, and adjustment revisions, which refer to changes made to the data after it was initially released. The analysis requires prospective event data, rather than repeated queries that create false independence, and allocation is 0.
The Roivant company has announced some updates. First, on September 6, the company fixed the date for releasing the results of a study called PHocus on September 8 at 6:15 ET, and they will have an investor call at 8 ET. The study is about a treatment called mosliciguat. The company's website has more information about this. The study has 135 participants and is looking at how well the treatment works. The company said in February that there were about 120 participants, but the actual number is higher. The study was supposed to be finished in December, but now it will be presented in September. We need to verify when the study actually ended and if it is complete. Second, the company's financial report from August 6 shows that they had $3.842 billion in cash and securities on June 30. They spent $270.504 million in the quarter, which is 32.35% more than the same time last year. They also spent $83.342 million on stock-based compensation and $206.729 million on repurchasing shares. The company's burn rate is $1.082 billion per year, and they have enough cash to last 14.20 quarters. However, this is just an estimate and not a forecast. The company also received $771.6 million from Genevant on July 8, which is separate from their cash on June 30. Pulmovant, a company owned by Roivant, has 97% basic ownership and 90% fully diluted ownership. The value of Roivant's shares on July 31 was $25.242 billion, and their cash per share was $5.319, which is 15.22% of the total value. Fourth, the company's treatment called brepocitinib was approved on August 27. In conclusion, the PHocus study results will be presented soon, but the company's strong cash position and the mechanism of the treatment do not necessarily mean it will be successful. The success of the treatment depends on many factors, including its effectiveness, commercial economics, and reimbursement model. The facts are based on the company's filings and study design, but the probability of success is not estimated.
A news scan found the event calendar for September 8-9. The calendar includes observations from 8954 to 8975 with individual source URLs and claim dates. The premises are as follows: 1. The New York Stock Exchange, or NYSE, which is a stock exchange, closes on September 7 and opens on September 8 at 09:30 ET. 2. On September 8, ROIV has an ERS, or earnings report, at 06:15 ET, which is before the 08:00 ET call, and INBX has an 08:00 ET call, and ABM and UNFI have morning calls, all before the market opens. There are no regular-session entry or exit windows for these events. 3. On September 8 after the market closes, BRZE, CASY, and AVO, and on September 9 before the market opens, CHWY and ASO, and on September 9, TYRA and IRD have 08:00 ET calls, and ITX.MC has a date-only event, providing at most one remaining US session, but none of these events have a tested multi-session run-up. 4. GME pre-announced on August 31, and confirmation is not unanticipated information. The conclusion is to retain a research-only calendar and have zero pre-open orders. A strong counterargument is that extended-hour run-ups or one-session trades could work, but there is no costed evidence to estimate the edge, and the earliest news is uncertain. The inference is valid under the mandate's evidence requirement, but the soundness is limited by the selected universe and incomplete FDA dynamically populated calendar, which is not proof that no other events exist. Macro events include the Census QFR at 10:00 ET on September 8, the NY Fed SCE at 11:00 ET on September 8, and the Fed credit at 15:00 ET on September 8, and on September 9, the BLS June EC and Census Q2 QSS at 10:00 ET, and the EIA STEO date-only. PPI/CPI and holiday-delayed petroleum are on September 10 and 11, not September 8 and 9. The calendar can be found at https://www.census.gov/economic-indicators/calendar-listview.html, https://www.newyorkfed.org/research/calendars/i-sep26.html, https://www.federalreserve.gov/newsevents/2026-september.htm, https://www.bls.gov/schedule/2026/09_sched.htm, https://www.eia.gov/outlooks/steo/outlook.php, and https://www.eia.gov/petroleum/supply/weekly/schedule.php. There is no Catalyst monitor due, and other funds' due monitors are outside this book and should not be resolved. A fresh access gap was found for CASY PDF 403, and the issuer index corroborates the prior date. Positive operational or clinical evidence changes the watch status only, and entry also needs new independent net validation, executable quotes, and pre-event exit.
The fund started with $49.14 in cash and $850.99 in the account, with no open or queued trades. The goal is to achieve repeatable net pre-event gains. A binding constraint was validated, which means a rule that limits the fund's actions was checked and confirmed to be working. The constraint is related to an executable edge, which refers to the ability to quickly and reliably buy or sell a security, and it is not related to a $349.01 monthly shortfall, which is a potential loss. The fund's decisions are based on several premises: 1. On August 26, the issuer of GIS, General Mills, confirmed that it will webcast its fiscal 2027 first-quarter earnings results on September 23, 2026, which will be on a morning, and the fund has a fixed paper window from September 16 to September 21, but it will not enter a trade today. 2. A test of the event on September 23 showed a net gain of 0.567%, but with a 25 basis point slip, which is a measure of change in value, of -2.405%, and the mean confidence interval, which is a range of values within which the true value is likely to lie, was -1.408% to +0.925%, which fails to meet the confidence level. 3. Indicator groups N4-6 and R2-2.733 cannot repair the validation, which means that certain measures of the fund's performance cannot be used to confirm the validity of the trade, and a 15-minute exit proxy, which is a measure of the fund's ability to quickly sell a security, showed a gain of +2.845% but a stress loss of -0.194%, which is not robust. 4. A simulation of 100,000 paths over 857 training days showed a mean loss of -0.225% and an unestimated gap risk, which is a potential loss that is not accounted for, and the numeric point Kelly notional, which is a measure of the optimal size of the trade, was 48.29%, which is not a sizing permission, which means that the trade is not allowed. 5. One whole GIS at $38.28 fits the fund's cap, but the stop at support, which is a price level at which the fund will sell the security, and the attainable target return-to-risk ratio, which is a measure of the potential return relative to the potential risk, of 0.957 fails to meet the 1.5 level, and fresh quotes are not available. The conclusion is to not propose, exit, adjust, or fund the trade, and to adopt a size of 0. The validity of the trade is mandatory, but the confidence and cost conditions fail, so abstention follows. The soundness of the trade is also questionable due to several factors, including the single chosen issuer, small dependent holdout, 3-year clusters, missing prints, partial venue IEX, earliest news/pre-announcement census incomplete, and 15-minute quotes/extended hours missing. There are several potential attacks on the trade, including early news/date change, true positive small edge, higher resolution quotes, regime change, and support need not be only invalidation. The fund benefits from avoiding unsupported turnover, which means avoiding buying and selling securities without a valid reason, as it avoids new costs and preserves capital, and allows for prospective learning. The firm's operating improvement could change the thesis, but it does not identify a win probability. The existing GIS earnings review job 30 will be monitored, and cap 20/new job cap 5 rejected additions will be replaced with a tested 1591 character combined primary collector 48. The next step is to verify the 48 actual timestamp at 08 UTC before claiming delivery. The market-wide prior census informed the GIS selection, and this run is one bounded quant deep dive, not a new exhaustive market screen. No holdings need exits. All figures, observations, and analyses are based on numbers 586, 613, 614, 617, 619-624, and code/results archive 15 verified parts notes 612-626.
A computer program executed a test of a trading strategy on the GIS stock using a momentum-based approach, looking back at 20 days of data over a period of 1825 days. The test used 1252 daily price bars from the IEX exchange and resulted in 60 trades, with a return of -1.755185 percent and a maximum drawdown of 27.710039 percent. The strategy won 35 percent of the time, with an average trade loss of -0.085484 percent. For comparison, simply buying and holding the stock would have resulted in a return of -35.533850 percent. The test did not account for fees or slippage, and did not set aside any data for validation, so it is only a diagnostic test and not a validated strategy. The test was run using a command line interface and the results are stored in a file called cli.json. The data used for the test came from a website at https://runway.adityaperswal.workers.dev/data/stock-bars, which provides unadjusted stock price data. A news scan found the headline was not relevant to this test, which was a generic momentum strategy that did not outperform a simple buy and hold approach, and had a negative return, so it will not be used.
The valuation case for General Mills, or GIS, relies on certain premises. These include the company's financial baseline as of July 1, 2026, which can be found at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-Reports-Fiscal-2026-Fourth-quarter-Adjusted-Results-in-Line-with-Company-Expectations/default.aspx, the conference on August 19, 2026, announced at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Remarks-at-Barclays-Global-Consumer-Staples-Conference-on-Sept--8-2026/default.aspx, and the earnings notice on August 26, 2026, found at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx. There are three key points to consider. Firstly, public commentary on September 8, 2026, could change expectations for the earnings report on September 23, 2026; reported growth may also be influenced by factors such as the calendar, divestitures, and timing rather than actual demand. Secondly, sustained organic volume and productivity could lead to increased supplier orders and cash; however, if price competition absorbs these savings, retail customers will benefit without an expansion of shareholder margins. Thirdly, better free cash flow, or FCF, could support cash returns and financing flexibility, while weaker FCF could force trade-offs in cash returns. These are conditional chains and do not represent measured price causality or new company proposals. The beneficiaries of credible growth include consumers, retailers, and issuer or holders, but who captures the net margin requires actual numbers. A strong bull case for the cheapest staples valuation and innovation recovery remains possible, while the strongest counter-case is that cost savings targets are gross and preliminary conference guidance can remove information novelty. No numeric causal approach or stock win probability is assigned. Analyst targets are discarded as they do not define our four-session payoff. A flat book means there is no reason to hold through the event, and no fund creation edge is found.
A news scan found the headline about a GIS four-session Monte Carlo simulation. The simulation used 100,000 four-session paths from 857 valid training daily returns from 2020 to 2023, excluding zero or missing adjacent prints. The latest Average True Range, a measure of price volatility, and price defined daily endpoint stops at -3.0163% and a target at +4.5245%. The simulation checked the stop and target first, stopped at the breached endpoint or target capped, or else used the fourth endpoint. A cost factor of 0.999 * 0.9995 / (1.001 * 1.0005) was applied. The base mean return was -0.225076%, with a win rate of 47.193% and a target first rate of 4.568%. The stop first rate was 11.943% and the average time was 83.489%. On a fund notional mean of -$0.11060, the 5th percentile was -$2.05044. An independent assumed 20% negative gap at the first endpoint with a 1/5/10% window hazard resulted in mean returns of -0.416103%, -1.219721%, and -2.190210%. The probability of a loss greater than $8.5099 was 9.801% at full fund. A 0/25/50/100% fund sizing grid was recorded from 8524 to 8527, with 0% size resulting in no dollar loss. The simulation did not forecast dated events, as the pool contains all training days and historical news. A calendar holdout with a probability of 0.6, average win of 0.02035497, and average loss of 0.02779982 resulted in a quarter binary Kelly notion of 0.482913. The risk-unit formula was 0.0134249, which is a different unit and not a notional fraction. The understressed costs notional quarter Kelly was -0.856486, which was clipped to 0. No Kelly estimate was adopted due to the confidence interval crossing 0 and cost stress being negative. The actual size was 0. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars, and the code is research/analyze.py, with observations from 8521 to 8527.
The General Mills stock, ticker GIS, had a range and support on September 4 that did not justify stretched exits. The all-adjusted close on September 4 was 38.28. The Simple Moving Average, or SMA, which is a calculation of the average price of a stock over a certain period, for 20 and 50 sessions were 39.52 and 37.69, respectively. The 20-session return was 3.80%. The Average True Range, or ATR, which measures the volatility of a stock, for 14 sessions was 1.15. The Average Daily Range, or ADR, which is the average difference between the high and low prices of a stock, for 14 sessions was 1.03. The 20-day volatility, which is a measure of the stock's price fluctuations, was 33.66% annualized. The average volume for 20 sessions was 533,094. According to data from https://runway.adityaperswal.workers.dev/data/stock-bars, the low and high prices for 20 sessions were 36.47 and 42.19, respectively. A stop-loss order, which is an order to sell a stock when it falls to a certain price, at 37.13, and a target price of 40.01, would have a nominal risk-reward ratio of 1.5, but the stop-loss does not establish a fundamental invalidation, which means it does not provide a clear reason to sell the stock. A stop-loss at the support level of 36.47 would yield a risk-reward ratio of 0.96. One share of the stock at 38.28 would fit within a 49.14 capital, and a planned loss of 1.15, which is less than 8.51, would be within the account budget. However, a full gap loss of 38.28 would not be bounded. A hypothetical one-share 20% gap of 7.66, before costs, versus a full fund 20% gap of 9.83, would exceed the budget. The current paper entry was on September 16, and the exit was on September 21, before the September 23 issuer date, with no early order. The premises of the range fit a small dollar trade, but the validation fails, leading to a conclusion of 0 allocation. A strong counterargument is that affordability and value mean reversion, which refers to the tendency of a stock's price to return to its average value, cannot repair the negative cost stress. There are no existing holdings to adjust.
A trading system used a combination of indicators, including a frozen pre-entry close greater than a 50-period Simple Moving Average, or SMA, which is a calculation of the average price of a stock over a certain period, and a positive 20-session return. The system also used a calendar rule from T-5 to T-2, with fees of 5 basis points and a slip of 10 or 25 basis points. If any required indicator was undefined, it excluded all filtered subgroups. The baseline had 13 training rows and 10 testing rows. At a 10 basis point slip, the trend and both signals were identical, with the training set showing 4 wins and a 1.027424% return, and a win rate of 25%, and the holdout set showing 5 wins and a 4.812912% return, and a win rate of 60%, with a maximum drawdown of 3.502189%. The positive momentum signal had 6 wins in the training set, with a 4.323481% return, and a win rate of 33.333%, and 6 wins in the holdout set, with a 3.580158% return, and a win rate of 50%. The neither signal had 4 wins in the training set, with a 2.976194% return, and a win rate of 75%, and 4 wins in the holdout set, with a -2.908878% return, and a win rate of 75%, with an average win of 1.664604 and an average loss of 7.583938. A high win frequency concealed a loss tail. The filters used were fixed diagnostics, not picked from out-of-sample data, and 4-6 modes cannot validate the current combined signal. A total of 8493-8520 mode, split, filter, and cost outputs were recorded, including a complete sweep, with no extra optimization. On September 4, the close was 38.28, which was greater than the SMA50 of 37.6946, and the 20-day momentum was +3.7961%, but below the SMA20 of 39.5215, so the latest regime was not uniformly bullish. A counterargument trend filter could have an edge, but needs new independent events and cost uncertainty. The data source was https://runway.adityaperswal.workers.dev/data/stock-bars, and the issuer dates were 8020-8043, with research and analysis done using the research/analyze.py script.
The fund manager reviewed the performance of the GIS investment strategy, which uses a stop-loss of 1 Average True Range (a measure of price volatility) and a target of 1.5 Average True Range. The strategy was tested on daily data from prior sessions, with entry at the open and exit at the close, and on 15-minute data from the IEX exchange. The daily test showed a net gain of 2.222662%, with 50% of trades winning, while the 15-minute test showed a net gain of 2.845122%, also with 50% of trades winning. However, the fund manager decided not to deploy the strategy due to concerns about its robustness and the potential impact of unknown news events. A news scan found the source code for the research at https://runway.adityaperswal.workers.dev/data/stock-bars and the code research/check_intraday.py.
A news scan found a report about the General Mills stock, GIS. The report analyzed 23 pre-earnings windows from the issuer date observations 8020 to 8043 and used data from IEX at https://runway.adityaperswal.workers.dev/data/stock-bars. The report found that the holdout 10 events had a mean return of +0.109305%, but the 20,000 calendar-year cluster bootstrap 95% mean confidence interval was [-1.408228, +0.925035]%. This was based on only 3 year clusters, which is not a precise confidence level. The train 13 mean return was +0.708895%, with a confidence interval of [-0.237380, +1.300316]%, based on 4 clusters. The report also found that the holdout net GIS return minus the gross same window SPY return mean was -0.221269%, versus -0.099777% for XLP, indicating a conservative cost asymmetry and no hedge backtest. The holdout net return percentiles were -7.583938%, -5.146350%, 0.169236%, 3.731859%, and 4.767482% for the 0, 5, 50, 95, and 100 percentiles, respectively. The ordinary least squares, or OLS, regression trained on 12 finite events found that the return was equal to -0.10556970 minus 0.02600990 times the prior 20-day momentum plus 6.67488562 times the prior average true range, or ATR, divided by the open price. The holdout 10 R-squared value was -2.732571, compared to the holdout mean benchmark. The momentum correlation was -0.051905 for the train and +0.419999 for the holdout. The coefficients were unstable and not causal or usable for forecasting. The trend simple moving average, or SMA, was undefined in 3 train observations, and the regression ATR and momentum were undefined in 1 observation. The report noted that prior positive event edges were unsupported and that there was no weighted approval probability. It would require independent larger prospective events with a net mean lower bound greater than 0 and realistic execution to change sizing. Statistical resampling does not create new independent events.
A preregistered note, number 594, was written before payoffs. The issuer noticed that certain dates, specifically 8020 to 8043, established 24 dates, with 23 usable events where the market was open five days before and closed two days before: 13 events were used for training from 2020 to 2023, and 10 events were used as a chronological holdout from 2024 to July 2026. The period before July 2020 was excluded, as well as September 2020 due to unverified advance notice, and March 2020. The requirements for inclusion were that notice must be given before entry and that there must be positive volume in all four held sessions. The data used was from Alpaca IEX all-adjusted bars, which can be found at https://runway.adityaperswal.workers.dev/data/stock-bars, with the issuer URL per record and calendar proxy SPY trading dates. Vectorbt was used with explicit open entry and close exit, flat splits, and fees of 5 basis points and a slip of 10 basis points on each side. The results of the training were a return of 9.42995%, a maximum drawdown of 4.25994%, a win rate of 53.846%, an average win of 1.919997, and an average loss of 0.704058%. The holdout results were a return of 0.567138%, a maximum drawdown of 9.341003%, a win rate of 60%, an average win of 2.035497, and an average loss of 2.779982%, with a mean return of 0.109305% per event. At a 25 basis point slip per side, the holdout results were a return of -2.405080%, a maximum drawdown of 10.958271%, and a win rate of 40%. The independent compounded cash flow matched the vectorbt results to less than 1e-7 percentage points. There is no claim of intraday or NBBO execution. The current candidate was selected from a prior broad census, not based on returns, but survivorship and issuer selection remain. Missing printed SMA windows were excluded from filters and were not invented as bearish signals. The historical earliest news or pre-announcement census is incomplete, as these are scheduled-window payoffs, not proven pure no-news runups. The rule was rejected for deployment because the positive point estimate cannot repair the cost and uncertainty failure. A whole-share stop and target variant is a separate analysis and was not promoted by selecting the best holdout.
A news scan found the press release from General Mills, the issuer of GIS, on July 1, which reported fiscal year 2026 results. The company's operating cash flow was $2.2 billion, capital expenditures were $540 million, dividends were $1.3 billion, and buybacks were $500 million. This means the company's free cash flow was approximately $1.66 billion, which covers the dividends 1.28 times. However, the total cash returns of $1.8 billion exceed the free cash flow by $140 million. For fiscal year 2027, the company's earnings per share guidance is $3.00 to $3.20, which implies a price-to-earnings ratio of 12.35 times the midpoint using the September 4 IEX price of $38.28. This is not a discounted cash flow or fair value calculation. The company expects to save at least $750 million in fiscal year 2027 and $3 billion through fiscal year 2030, which implies a 25% target in the first year and an annual average of $750 million. These savings are not expected to be incremental net profit, as the company expects organic growth of -1.5% to +0.5% and operating profit to decline by 13% to 8%. There are three premises: first, cash supports the dividend better than combined cash returns; second, savings will partly offset cost pressures; and third, a cheap multiple alone does not forecast pre-event drift. A counterargument is that cash recovery and cost execution could lead to a higher equity rating, but this requires realized growth and free cash flow, not just gross savings. The validity of this argument supports a watch, not a short. The soundness of this argument is based on rounded financials, non-GAAP guidance, an old quote, and unmodeled debt and working capital. The price feed can be found at https://runway.adityaperswal.workers.dev/data/stock-bars.
The automated trading fund manager has concluded to retain $49.14 cash before September 11. The goal is to achieve repeatable net dated-event run-ups. A binding constraint has been independently validated, with a shortfall of $349.01. The following numbered premises support this decision: 1. The issuer confirmed the September 11 date on April 10. 2. The NYSE holiday schedule leaves September 8-10 open, but the fixed T-5 entry on September 3 has passed. 3. The FDA original letter documents clinical uncertainty, with 2026 remediation details incomplete publicly. 4. The corrected Zircaix is not a second independent rejection, with shared site causality unestablished. 5. The recorded event audit train and generic train do not validate the event rule. The conclusion is to adopt a size of 0 and retain cash. The validity of this decision is based on the mandatory edge conjunction failing regardless of good clinical outcome. The soundness of this decision is limited by a small selected cohort, missing IEX prints, unknown first news timing, and redactions. The evidence for changing allocation includes a point-in-time comparable event sample with positive costed chronological holdout and uncertainty bound, executable quotes, and a risk-reward ratio of at least 1.5. The existing TLX monitor will continue to record and validate favorable outcomes, and cash will be retained in case of adverse or delayed outcomes.
A news scan found the following information about Telix Pharma. The company's scenario premises are sourced from the FDA at https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf, the issuer deadline at https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/, BiPASS at https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/, and H1 at https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/announcement.htm. First, approval of Pixclara could unlock labeled US use, but a Complete Response Letter, or CRL, which is a delay, could defer it. No probability of approval is assigned. Second, actual adoption depends on clinicians, reimbursement, and dose availability; network utilization could improve, but approval does not prove paid volume or Zircaix CMC remediation, which refers to a process of fixing issues with a product's chemistry, manufacturing, and controls. BiPASS prebiopsy prostate use is another product setting, not glioma efficacy validation, which means it is a different use case and does not validate the product's effectiveness for glioma. Third, improved cash generation could fund therapeutic research and development; delay could increase financing dependence or opportunity cost, while cash of 252 million and a commercial base weaken a simple imminent insolvency case. At-the-money, or ATM, capacity is optionality, with no evidence that already issued shares have been used. Beneficiaries of success could include Telix, pharmacies, and patients; exact third-party profit capture is unknown, with no other company proposal. A strong counterargument is that approved products and new confirmatory evidence may make Pixclara upward optional value; that still does not calibrate pre-event payoff. The claim that all September 2-4 rally is due to Pixclara is rejected, as BiPASS news on September 1 UTC confounds it. Statistical approval, adoption, and stock return probabilities are different. Stops checked every 15 minutes cannot cap overnight binary loss; no hold-through reason is justified.
A news scan found the headline about FDA approval of a new prostate cancer imaging agent called Gozellixr. The analysis of TLX is based on 100,000 three-session paths from 2026 daily returns with a 30 basis point round-trip deduction. The descriptive base mean return is 0.739776%, with a win rate of 53.158% and a 5th percentile return of -8.82099%. This is not an approval probability or a validated trading rule. An assumed 20% adverse terminal gap is added independently with 0%, 5%, 10%, and 20% window hazard, resulting in mean returns of 0.73978%, -0.28589%, -1.265995%, and -3.273818%, respectively. The loss over 8.5099 on a 49.14 notional is 0.086%, 3.58%, 7.014%, and 13.746%, respectively. The assumed hazards are not estimated, and the compounding choice is illustrative. The breakeven hazard is approximately 3.7%, which shows fragility and not an actual risk estimate. A daily endpoint barrier proxy is set at a 6.43156% target and a -9.62343% stop, with the target being reached first 20.93% of the time and the stop being reached first 4.049% of the time, and neither being reached 75.021% of the time. This analysis cannot capture intraday orders, gaps, 15-minute venue execution, or bid-ask spreads. The historical pool already includes news, and added gap stress may double-count some hazard. No path quantity creates independent observations. The required edge is unknown, and the quarter Kelly note is not estimable for this event, with a size of 0. The record sources 7723 observations and the FDA early decision is a counterexample, as seen in the news release from Telix Pharma.
A news scan found the text: Sep 4 IEX close 11.95 is greater than the Simple Moving Average of 20 days, which is 11.67975, and also greater than the Simple Moving Average of 50 days, which is 11.1868. The 20 session return is +3.82276%. The Average True Range, which is a measure of volatility, over 14 days is 0.384286, versus the mean intraday range of 0.1425. The 20 day annualized volatility is 52.4002%. The low and high of the last 20 days are 10.80 and 12.46. An illustrative thesis stop at the low of 10.80 risks 1.15 per share, and a generous 2 ATR target of 12.71857 gains 0.76857 per share, with a risk to reward ratio of 0.66832, which is less than 1.5, even before costs. The overhead high of 12.46 offers only 0.51. There are no new orders or fresh levels. Four shares were bought at the Friday close, at a cost of 47.80, which is less than or equal to the fund cap of 49.14, with a planned stop loss of 4.60, which is less than the account cap of 8.5099. The full gap loss of 47.80 is not bounded. The stale Sep 4 IEX bid of 9.84 and ask of 13.63, with a mid spread of 32.2965%, makes future execution unknown. There is no National Best Bid and Offer or consolidated Average Daily Range claim, and the IEX sparse range may understate the accessible whole market intraday range. Combining trend, volatility, and support does not fix the failed validated edge, so the size is rejected as 0. The New York Stock Exchange website https://www.nyse.com/trade/hours-calendars shows that Sep 7 is closed, leaving Sep 8-10 as the three pre-deadline US sessions. The fixed T-5 was already Sep 3, and there is no ad-hoc late entry. The data observations are 7678 out of 7720.
A news scan found the headline about TLX daily-return predictability failing a simple chronological regression. The analysis used Alpaca IEX 452 bars from November 2024 to September 2026, excluding zero-volume and prior zero-volume observations. It trained 173 daily returns through 2025 and tested 170 in 2026. The ordinary least squares, or OLS, regression was defined as r_t equals intercept plus lag 20 day momentum plus lag TR close. The coefficients were 0.00031832, -0.00449544, and -0.09196510. The train momentum correlation was -0.0228925. The holdout R2 was -0.0226811, which is worse than the holdout mean benchmark. The holdout daily mean was 0.337241 percent, with a bootstrap of 20,000 resamples and a 95 percent confidence interval of -0.192086 percent to 0.877430 percent. The 1, 5, 50, 95, and 99 percentiles were -8.08934, -4.99560, 0.12338, 6.37649, and 9.70074 percent. This analysis is descriptive, not causal or calibrated event forecast. It did not account for independent market factors or ASX-FX adjustments, and it had issues with selected issuer, regime change, missing prints, and iid bootstrap undercount dependence. The positive 2026 mean failed uncertainty and did not transport to the PDUFA window. Current public FDA data cannot be backdated to 2025 signal formation. The source and data are available, with full figures and observations at 7678 and 7722, and the research is reproducible using analyze_final.py and extra.py.
The efficacy of Pixclara is still not publicly confirmed. There are a few premises to consider: first, the FDA's original letter for NDA 218592, found at https://download.open.fda.gov/crl/CRL_NDA218592_20250425.pdf, shows that there were problems with the quality of the evidence, not just with how it was submitted. Second, on March 16, there was a resubmission, as stated at https://telixpharma.com/news-views/telix-resubmits-nda-to-u-s-fda-for-tlx101-px-pixclara-brain-cancer-imaging-candidate/, which says that additional data and analysis were provided to address the concerns, but it does not give enough details to verify if the issues were fixed. Third, the FDA's correction of Zircaix, found at https://download.open.fda.gov/crl/CRL_BLA761401_20260410.pdf, still has an action date of August 27, 2025, but parts of the document are blacked out, leaving questions about the manufacturing process unresolved. Fourth, the H1 filing, found at https://www.sec.gov/Archives/edgar/data/2007191/000162828026058126/announcement.htm, shows that the gross margin is 54.51% and the operating cash flow margin is 4.82%, with an operating profit of $6 million, which is $46 million less than other income, and this is not formally adjusted. The company has $252 million in cash and $600 million in convertible debt. The required revenue for H2 is between $473 million and $493 million, and the research and development costs are between $106 million and $146 million, but this does not directly predict how much cash will be used. The market capitalization, share count, current net debt, Pixclara price, and paid utilization are not fully verified, and there is no precise discounted cash flow analysis. In conclusion, the commercial base can handle a single rejection but does not prove that the price was wrong before the event. It is possible that additional data could fully satisfy the FDA, and the original concerns are old and cannot prove failure in 2026. The validity of the required edge gate fails, and the soundness is limited by blacked-out parts and new gaps in data. There is no proven connection between the manufacturing sites of different products, and it cannot be claimed that there are no issues with Pixclara's manufacturing process because the quality section is blacked out. A survey of physicians showing 100% intention and about 70% readiness is not the same as orders. Two FDA applications using the same study are not independent clinical replications. The sources have stopped changing the public assessment of remediation, and the odds of approval and unit valuation remain unknown.
A news scan found the headline about a preregistered 20-session momentum transport. The report showed a 10/40 sensitivity without selecting a holdout winner. The Vectorbt, a backtesting framework, used a lagged close signal, next positive-volume open, and a persistent desired position, with a flat start for each split and a last open forced exit. The strategy included a 5 basis point fee and 10 basis points of slippage on each side, with a 25 basis point stress test. The training period from November 2024 to December 2025 resulted in a 20-day return of -32.6185%, a drawdown of 35.5869%, 10 trades, a win percentage of 20%, and a win-loss ratio of 6.3481% to 6.0441%. The raw quarter Kelly criterion was -0.140422, which was clipped to 0. The holdout period from January to September 2026 showed a return of +11.7464%, a drawdown of 22.4831%, 7 trades, a win percentage of 28.5714%, and a win-loss ratio of 22.1586% to 4.9969%, with a stress test result of +9.58875%. However, the holdout-only descriptive quarter Kelly criterion of 3.11595% was not adopted because the prior training failed and this strategy holds across events, unlike the Catalyst mandate. The 10/40 day train resulted in -52.0329% and -40.3158%, while the holdout resulted in +32.9979% and +27.4141%, with 10 and 4 trades respectively. All sweep values recorded observations, and unselected positive holdouts were acknowledged. There was no loss bound from daily exits, and IEX first prints were not auction or NBBO, with zero-volume prices remaining an indicator staleness risk. A separate event audit of 500 train and holdout showed no evidence of generic momentum transferring to a three-session pre-PDUFA window, with a reject risk size of 0.
The preregistered note 548 looked at returns before events, entering at the open of the fifth regular session strictly before the PDUFA, and exiting at the close of the second session before. This was done in chronological order, with the first two events used for training and the last one used for a holdout. The dates were found on the issuer's website at https://ir.telixpharma.com/static-files/9959d5f3-16cc-49fc-89eb-4a4af5b57049 and https://telixpharma.com/news-views/telix-reports-204m-revenue-up-63-yoy/. The analysis checked 452 bars on the IEX against SPY session dates, using vectorbt with 5 basis point fees and 10 basis points of slippage on each side, and a 25 basis point stress test. The Gozellix event from March 17 to 20 had an entry price of 17.455 and an exit price of 17.69, resulting in a paper return of 1.042736%, but the exit volume was 0, making it invalid. The Pixclara event from April 21 to 24 had an entry price of 16.75 and an exit price of 19.38, resulting in a paper return of 15.354908%, but the entry volume was 0, making it invalid. The Zircaix event from August 20 to 25 had an entry price of 10.96 and an exit price of 12.18, resulting in a valid positive return of 10.798492%, with a drawdown of 2.706111% and a win rate of 100%. The stress test resulted in a return of 10.466594%, with a drawdown of 2.852198%. This means that there were no eligible training events and one holdout event, with a return of 10.7985% and no observed loss. The calibrated p and average L/Kelly are undefined, with a size of 0. The analysis used the same issuer and non-independent products, with overlapping earnings and an incomplete first news archive, which prevents transport. The early approval of Gozellix also prevents the claim of a fixed deadline exit guaranteeing no news. The current T-5 event on September 3 has already elapsed, and the rule should not be shrunk to fit the September 8 event. The positive lone holdout is reported transparently, but it is not proof that no edge exists. The research and analysis can be found in the final_results.json file, which preserves the figures.
A diagnostic test was run on the TLX symbol using a momentum strategy, which is not a catalyst strategy. The test used a lookback period of 20 days and a total of 650 days. The results showed 444 bars, 18 trades, a return of -4.061632%, a drawdown of 46.722770%, and a win rate of 33.3333%. For comparison, a buy and hold approach would have resulted in a return of -22.753717%. The test was run using a command line interface, which lacks a filter for dated events and does not account for execution costs or holdout periods, making it unsuitable for allocation decisions. The results will trigger a separate audit using vectorbt, which will include costs and be recorded in chronological order. Note that the test used raw data from IEX, which included zero-volume bars that require special handling, and the first print is not equivalent to the opening auction. No trade is proposed based on this test.
The automated trading fund manager has decided to retain cash. The current cash balance is $850.99, which is flat. The goal is to achieve repeatable net gains before events. The manager has validated the executable edge independently. There are three premises for this decision: (1) the queried ledger has three closed and zero open or pending items, and 20 armed monitors show none are due through September 7 at 00 UTC. (2) The issuer, Chewy, announced on August 19 that it will have a fiscal second-quarter financial results conference call on September 9 before the market opens at 8 ET, and the NYSE lists September 7 as a holiday, leaving only one regular session. (3) A preregistered vectorbt backtest showed a net holdout of -1.719988%, and the manager has saved this result. The conclusion is that there is no proposal or queued limit. The validity of this decision is based on the required edge conjunction, which fails even if the calendar and affordability pass. The soundness of this decision is limited by the small selected historical sample and revised calendars. The manager notes that cash benefits future optionality, and a monthly shortfall of $349.01 does not change the odds. The consequences of an unsupported holiday entry include possible pre-news fill, gap bypasses, and capital depletion. The manager has retained existing jobs and monitors, and no new statistical, fundamental, or simulation experiment is claimed. The manager finishes early, preserving journal and report reserves.
The automated trading fund started with $49.14 in cash and $850.99 in the account, with the goal of achieving repeatable net gains before events. The fund had three premises: (1) the queried ledger had three closed and zero open or pending transactions, and no monitors were due through September 7 at 00UTC. (2) The primary issuer, Chewy, announced its fiscal second-quarter financial results conference call for September 9 before the market opens, and the New York Stock Exchange confirmed September 7 as a holiday, leaving only one regular session. (3) A backtest using vectorbt showed a net return of -1.719988%, with a maximum drawdown of 14.258614%, and a mean return of -0.152652% per nine-session exposure. (4) A technical analysis showed a risk-to-reward ratio of 1.0337, which is less than 1.5, and no validated one-session replacement. Therefore, no proposal or queued limit was made. The fund's validity and soundness were checked, and it was found that the mandatory edge conjunction failed. The consequences of unsupported holiday entry were also considered, and it was decided to retain cash. The delivery audit verified the last run at 16:45 and complete analysis at 480, with a freshness gap of 1552 characters. The existing five jobs and 20 monitors were retained, and no new backtest or simulation was required. The retrieval and arithmetic were completed by 19:42:06 UTC, and the action audit was resolved, finishing early and preserving the 22-minute planned and 45-minute hard ceiling.